Clinical Research Institute at Rambam
|
"Advances in the medical sciences have shifted the focus of healthcare from treating symptoms by trial and error towards addressing the fundamental causes of disease as rooted in group and individual genetic features and predispositions."
Prof. Karl Skorecki, Director, Medical & Research Development, RHCC |
The number of people worldwide expected to suffer from diabetes mellitus and its complications is anticipated to more than double from 150 million to 350 million affected individuals by the year 2025 unless global-scale, preemptive measures are taken. Rambam proposes establishing a prototype, replicable and exportable Center of Excellence whose clinician-researchers will explore such issues as:
» The population genetics of metabolic disease and diabetes mellitus in Northern Israel
» The mechanisms driving the relationship between low birth weight and development of adult metabolic syndrome and diabetes mellitus
» Medical-psychology applications to type 1 diabetes mellitus
» Pre-clinical detection and prevention of autoimmune (type 1) and metabolic-syndrome related type 2 diabetes mellitus
» The cellular and molecular mechanisms of energy utilization and mitochondrial DNA in relation to the pathogenesis of type 2 diabetes mellitus
» Beta-cell regeneration therapy
» Glucose-control device technology
» The prevention and remission of established diabetes-mellitus complications: vision loss, limb loss, kidney failure, stroke and heart attack